NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.
NeRRe Therapeutics has raised $27.6M in total funding. The most recent round was Series B. The last funding was announced in July 2021.
NeRRe Therapeutics's investors include Novo Holdings, OrbiMed, Forbion Capital Partners, Columbus Venture Partners, Fountain Healthcare Partners.
NeRRe Therapeutics is headquartered in Stevenage, United Kingdom.
NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.
NeRRe Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NeRRe Therapeutics — Funding & Investors." VCBacked, July 7, 2021, https://www.vcbacked.co/company/nerre-therapeutics. Accessed September 29, 2026.
VCBacked. (2021). NeRRe Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/nerre-therapeutics
{{cite web |title=NeRRe Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nerre-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated